XML 22 R9.htm IDEA: XBRL DOCUMENT v3.26.1
Revenues
3 Months Ended
Mar. 31, 2026
Revenues.  
Revenues

3. Revenues

The Company recorded product revenues from the U.S. sales of CARDAMYST of $0.2 million for the three months ended March 31, 2026, and no revenue for the three months ended March 31, 2025.

The Company recorded no license revenue for the three months ended March 31, 2026, and 2025, respectively.